Eye News and Research

Latest Eye News and Research

Researchers develop integrated treatment program for PTSD affected veterans

The wars in Iraq and Afghanistan have resulted in a growing number of soldiers evacuated to the United States for comprehensive care for physical and psychological trauma. Given the number of physical injuries often experienced by soldiers, it is not surprising that chronic pain is a frequent problem among returning soldiers from Operation Iraqi Freedom and Operation Enduring Freedom (OIF/OEF). Common sources of pain are in the head (traumatic-brain injury or post-concussion syndrome), legs (fractures, amputations, burns) and shoulders.

1 Oct 2009

ORBIS' Childhood Blindness Initiative aims to develop 50 pediatric ophthalmology centers across India

ORBIS International's flagship Flying Eye Hospital arrived in Jaipur, India with its international team of volunteer eye care specialists and global sponsor Alcon, Inc. (NYSE: ACL), the world's leading eye care company.

1 Oct 2009

Alcoholism affects sleep even after long periods of abstinence for both men and women, says study

A study in the Oct.1 issue of the journal Sleep shows that long-term alcoholism affects sleep even after long periods of abstinence, and the pattern of this effect is similar in both men and women.

1 Oct 2009

Latest optical and laser technology in medicine displayed at FiO meeting

From scopes that help premature babies breathe to techniques for imaging live neurons and beating hearts as they develop, the latest optical and laser technology being deployed in medicine and the biosciences will be on display at the Optical Society's (OSA) Annual Meeting, Frontiers in Optics (FiO), which takes place Oct. 11-15 at the Fairmont San Jose Hotel and the Sainte Claire Hotel in San Jose, Calif.

1 Oct 2009

Can-Fite BioPharma commences preparatory work for a Phase III trial with CF101 to treat Psoriasis

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to severe Psoriasis; the study successfully met its primary objective of efficacy and safety

1 Oct 2009

MacuSight's clinical development update on its proprietary ocular sirolimus product

MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today provided a clinical development update for Perceiva, the company's proprietary ocular sirolimus product.

30 Sep 2009

Omega-3 fatty acids prevent and slow age-related macular degeneration

Researchers are seeing more benefits of omega-3 fatty acids (omega-3s), such as their ability to help prevent and slow age-related macular degeneration (AMD), an eye disease that is the leading cause of severe vision loss in older people.

30 Sep 2009

Phase III clinical trial results demonstrate effectiveness of spinosad suspension

ParaPRO, LLC announced today the results of two Phase III clinical studies published online this month in the journal Pediatrics (Pediatrics 2009; 124:e389-e395) which concluded that a spinosad suspension was significantly more effective in eliminating head lice (pediculosis capitis) than permethrin.

30 Sep 2009

New cost-effective dental and vision care coverage options from UnitedHealthcare

UnitedHealthcare’s Golden Rule Insurance Company has introduced new cost-effective dental and vision care coverage options for individuals and families in Alaska, Arizona, Colorado, Iowa, South Dakota and Wyoming.

30 Sep 2009

pSivida reports interim results of human PK study of Iluvien

pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.

29 Sep 2009

IP Advocate founder to speak on commercialization barriers faced by university faculty inventors

Speaking of the then-divided Berlin, former President Reagan famously admonished Soviet leader Gorbachev to “tear down this wall.” In a similar spirit, IP Advocate founder Dr. Renee Kaswan is calling on the university technology transfer system to remove the barriers that keep innovations from moving swiftly into the marketplace.

29 Sep 2009

Blood vessels in the retina may help predict risk of heart attack or stroke

For centuries eyes have been seen as windows to the soul. But medical researchers now believe the eyes may also offer vital clues to your risk of heart disease and stroke.

28 Sep 2009

Progress on the Baucus Bill is in the eye of the beholder

The New York Times: "Senate Democrats on Friday preserved the guts of their proposal to reinvent the health care system, but Republicans scored political points on several issues, like the effects of the bill on older Americans. The Democrats beat back Republican attacks on the legislation as the Senate Finance Committee deferred some of the most contentious issues to next week."

28 Sep 2009

Network in Canada to develop biomaterials for treatment of eye diseases

Researchers in Canada have established a new university/industry network to pursue the development of biomaterials, medical devices and drug delivery systems to treat the increasing incidence of eye disease.

26 Sep 2009

ethica Clinical Research, Matrix Pharma sign worldwide agreement

ethica Clinical Research Inc. ("ethica"), a Contract Research Organization (CRO) headquartered in Montreal, and Matrix Pharma Canada Inc. ("Matrix Pharma"), have announced the signing of an agreement, valued at CAD1.25 Million, that provides ethica with an exclusive, worldwide license to promote and use Matrix Pharma's proprietary research data analysis technology for life sciences applications, notably for the identification and optimization of biomarkers.

25 Sep 2009

Adaptive Eyewear's endeavors to build vision infrastructure in Rwanda

Adaptive Eyewear, a UK-based not-for-profit organisation which aims to provide vision correction solutions to people in the developing world, was recognized yesterday at the Clinton Global Initiative (CGI) Fifth Annual Meeting for its exemplary approach to address the significant shortage of eye care specialists and lack of vision infrastructure in Rwanda. Adaptive Eyewear's commitment to the people of Rwanda was announced at the session "Driving Disruptive Innovation at the Base of the Pyramid" on Wednesday 23rd September at 2:45pm.

25 Sep 2009

Students live with elder residents as part of the Learning by Living project

A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.

25 Sep 2009

Children with minimal change nephrotic syndrome can be treated with prednisone

A kidney condition that can arise in children and was until recently believed to disappear after puberty may persist into adulthood and cause significant long-term complications, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate that better treatment options are needed for children with the disorder, called minimal change nephrotic syndrome.

25 Sep 2009

Commitments announced at the Clinton Global Initiative

The second day of the Fifth Annual Meeting of the Clinton Global Initiative (CGI) came to a close with a special session on Northern Ireland, following afternoon plenary and breakout sessions that focused on harnessing innovation for development.

24 Sep 2009

ThromboGenics completes enrollment for MIVI-TRUST clinical trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the US Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

24 Sep 2009